Clinic
Infuseable Healthcare, LLC
Infuseable Healthcare, LLC was paid $643K by Medicaid between Jul 2021 and Dec 2024, across 20 billing codes. Its largest line is J0491, Injection, anifrolumab-fnia, 1 mg — 22% of everything it billed.
33Billing provider infoINFUSEABLE HEALTHCARE, LLC
SCOTTSDALE, AZ 85260
SCOTTSDALE, AZ 85260
33aNPI1689288938assigned 09/03/2020
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$643K
24GClaims8,819
24DCodes billed20
24AFirst – last monthJul 2021 – Dec 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in Arizona
Rank by total paid#43 of 76
Median peer was paid$899K
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 322 | $12K | |
| 2022 | 2,232 | $239K | |
| 2023 | 3,460 | $195K | |
| 2024incomplete | 2,805 | $197K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J0491 | Injection, anifrolumab-fnia, 1 mg | 22% | 90 | 72 | $142K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 19% | 3,186 | 2,016 | $121K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 14% | 1,175 | 944 | $89K |
| Q5121 | Injection, infliximab-axxq, biosimilar, (avsola), 10 mg | 10% | 75 | 65 | $67K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 10% | 111 | 71 | $66K |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 7.8% | 14 | 12 | $51K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 6.7% | 41 | 39 | $43K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.6% | 1,017 | 716 | $17K |
| J0490 | Injection, belimumab, 10 mg | 2.1% | 31 | 26 | $13K |
| 96415 | 1.6% | 423 | 340 | $10K | |
| J1756 | Injection, iron sucrose, 1 mg | 1.5% | 547 | 254 | $10K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.1% | 278 | 213 | $7K |
8 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 455 | $4K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 200 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 709 | $1K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 12 | $625.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 127 | $549.37 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 241 | $320.08 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 67 | $116.45 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 20 | $6.88 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTURK, CALLIE (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Bonhoeffer Rheumatology Institute, LLC | Gilbert, AZ | $315K |
| Flexcare Infusion Okc, LLC | Oklahoma City, OK | $164K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.